Novavax (NVAX) Return on Sales (2010 - 2026)

Novavax's Return on Sales history runs 17 years deep, the most recent figure standing at 0.0% for Q1 2026.

• On a quarterly basis, Return on Sales fell 1.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.0%, a 1.0% decrease from a year earlier, with the FY2025 full-year figure at 0.0%, up 1.0% from the prior year.
• Return on Sales eased to 0.0% in Q1 2026 per NVAX's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q1 2025 and bottomed at 0.04% in Q1 2023.
• The 5-year median for Return on Sales is 0.01% (2022), against an average of 0.01%.
• Across the five-year window, Return on Sales gained 3 bps in 2022 and declined 4 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 0.01% in 2022, then declined by 20 bps to 0.01% in 2023, then plunged by 50 bps to 0.01% in 2024, then soared by 113 bps to 0.0% in 2025, then plunged by 157 bps to 0.0% in 2026.
• Per Business Quant, the three latest NVAX Return on Sales figures stand at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.03% (Q3 2025).